Literature DB >> 7775139

Phase II trial of 6-thioguanine in advanced renal cell carcinoma. An Illinois Cancer Center study.

D H Shevrin1, L J Kilton, T E Lad, M Mullane, B Esparaz, R Knop, J Egner, P Johnson, R Blough, S French.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7775139     DOI： 10.1007/bf00873053

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  4 in total

1.  Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma.

Authors:  P H Konits; M J Egorin; D A Van Echo; J Aisner; P A Andrews; M E May; N R Bachur; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine.

Authors:  J A Nelson; J W Carpenter; L M Rose; D J Adamson
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

3.  Thioguanine-induced S and G2 blocks and their significance to the mechanism of cytotoxicity.

Authors:  L L Wotring; J L Roti Roti
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

4.  Phase I trial of parenteral 6-thioguanine given on 5 consecutive days.

Authors:  J S Kovach; J Rubin; E T Creagan; A J Schutt; L K Kvols; P A Svingen; T C Hu
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.